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Glomerular endothelial cell (GEnC) dysfunction is important in the pathogenesis of
glomerular sclerotic diseases, including Focal Segmental Glomerulosclerosis (FSGS)
and overt diabetic nephropathy (DN). GEnCs form the first cellular barrier in direct
contact with cells and factors circulating in the blood. Disturbances in these circulating
factors can induce GEnC dysfunction. GEnC dysfunction occurs in early stages of FSGS
and DN, and is characterized by a compromised endothelial glycocalyx, an inflammatory
phenotype, mitochondrial damage and oxidative stress, aberrant cell signaling, and
endothelial-to-mesenchymal transition (EndMT). GEnCs are in an interdependent
relationship with podocytes and mesangial cells, which involves bidirectional cross-talk
via intercellular signaling. Given that GEnC behavior directly influences podocyte function,
it is conceivable that GEnC dysfunction may culminate in podocyte damage, proteinuria,
subsequent mesangial activation, and ultimately glomerulosclerosis. Indeed, GEnC
dysfunction is sufficient to cause podocyte injury, proteinuria and activation of
mesangial cells. Aberrant gene expression patterns largely contribute to GEnC
dysfunction and epigenetic changes seem to be involved in causing aberrant
transcription. This review summarizes literature that uncovers the importance of cross-
talk between GEnCs and podocytes, and GEnCs and mesangial cells in the context of the
development of FSGS and DN, and the potential use of GEnCs as efficacious cellular
target to pharmacologically halt development and progression of DN and FSGS.
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THE KIDNEY AND THE GLOMERULUS
The kidneys have a vital role in fluid homeostasis and osmoregulation. Additionally, the kidneys
are important for control of blood pressure and mineral metabolism. By filtering blood in the
glomeruli, the kidneys produce about 150 liter glomerular filtrate per day of which 99% is
reabsorbed in the tubules, to eventually generate approximately 1 liter of urine per day. By blood
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filtration and tubular excretion, waste products such as urea,
minerals and toxic substances, are excreted from the body.
The glomerulus is a network of capillary loops, known as the
glomerular tuft, and is enclosed by the Bowman’s capsule. Blood
flows into the glomerulus via the afferent arteriole and leaves the
glomerulus via the efferent arteriole (Scott and Quaggin, 2015).
The glomerulus is assembled by four different cell types: parietal
epithelial cells, glomerular endothelial cells (GEnCs), podocytes
(visceral epithelial cells), and mesangial cells (Figures 1A, B).
Parietal epithelial cells line the Bowman’s capsule, where the pre-
urine is collected and forwarded to the proximal tubule. GEnCs
cover the luminal surface of glomerular capillaries and are the
cells of the glomerulus in direct contact with the blood. GEnCs
are characterized by transcellular pores (i.e., fenestrae), essential
for blood filtration. At the adluminal side, GEnCs are covered
with the endothelial glycocalyx, filling the fenestrae (Satchell,
2013; Scott and Quaggin, 2015; Hegermann et al., 2016) (Figure
1C). The endothelial glycocalyx is a gel-like layer consisting of
glycoproteins, proteoglycans with bound glycosaminoglycans
(GAGs) (Reitsma et al., 2007; Slater et al., 2012; Garsen et al.,
2014; Dane et al., 2015) and plasma proteins loosely adherent
within the meshwork of the glycocalyx. The endothelial
glycocalyx prevents leakage of circulating plasma proteins by
size and steric hindrance and electrostatic repulsion (Ryan and
Karnovsky, 1976; Singh et al., 2007; Patrakka and Tryggvason,
2010; Friden et al., 2011; Dane et al., 2013), and inhibits adhesion
and extravasation of inflammatory cells.
The endothelial glycocalyx serves as the primary sensor of
wall shear stress through the initiation of signal transduction in
GEnCs (Tarbell and Ebong, 2008). Wall shear stress, the
hydrodynamic frictional force created from blood flow,
transmits through the endothelial glycocalyx into the GEnC,
leading to signal transduction that subsequently regulates the
expression of Krüppel Like Factor 2 (KLF2), KLF4 and the
transcription of eNOS and the production of nitric oxide (NO)
which are crucial to maintain GEnC function (Dekker et al.,
2006; Weinbaum et al., 2007; Ohnesorge et al., 2010; Slater et al.,
2012; Dogne et al., 2018). In addition, GEnCs also function as a
sink for factors essential for the regulation of the vascular tone
and cross-talk with other glomerular cell types, such as
vasoactive factors (endothelin-1 (ET-1), and NO) (Feliers et al.,
2005; Dhaun et al., 2012).
Podocytes are specialized perivascular epithelial cells with
elaborate projections called foot processes that are intimately
wrapped around the exterior of glomerular capillaries (Figures
1B, C). The foot processes leave slits between them, called slit
diaphragms, which are instrumental for proper blood filtration.
GEnCs and podocytes share a common extracellular matrix,
referred to as the glomerular basement membrane (GBM), which
separates the GEnCs from the podocytes. Together, the GEnCs
and the endothelial glycocalyx, the GBM, and the podocytes
constitute the glomerular filtration barrier (GFB). The GFB is
responsible for size-selective and charge-dependent filtration of




FIGURE 1 | The kidney, glomerulus, and the glomerular filtration barrier. Each kidney consists of about 1 million nephrons. Each nephron consists of a glomerulus
and a tubular compartment (A). The glomerulus is assembled by four different cell types, namely parietal epithelial cells, glomerular endothelial cells (GEnC),
podocytes (visceral epithelial cells), and mesangial cells (B). GEnC and podocytes share a common extracellular matrix, the glomerular basement membrane (GBM).
GEnC and their fenestrae are covered by the endothelial glycocalyx. Podocytes contain foot processes with slit diaphragms that are wrapped around the exterior of
glomerular capillaries. Together, the GEnC and the endothelial glycocalyx, GBM and podocytes comprise the glomerular filtration barrier to filter the blood and
remaining essential plasma proteins in the circulation (C). RBC, Red Blood Cell; GBM, Glomerular Basement Membrane; GEnC, Glomerular Endothelial Cell.
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glucose, amino acids, and minerals can pass the GFB freely,
whereas circulating cells and large and negatively charged
proteins, including albumin, cannot pass the GFB. Mesangial
cells are located in between the capillaries and form the
mesangium together with their extracellular matrix (ECM).
The mesangium provides structural stability to the glomerular
vasculature and modulates capillary blood flow (Scott and
Quaggin, 2015). The functionality and integrity of the GFB
depends on proper function of GEnCs, podocytes and
mesangial cells. Dysfunction of any of the cellular or
extracellular components of the GFB culminates in a decreased
filtration and eventually glomerulosclerosis (Haraldsson and
Nystrom, 2012; Fu et al., 2015).
CROSS-TALK BETWEEN GLOMERULAR
CELLS IS ESSENTIAL FOR GLOMERULAR
INTEGRITY
There is a growing understanding of the interdependent
relationship between GEnCs, podocytes and mesangial cells,
which involves bidirectional cross-talk at a molecular level. To
exemplify the importance of cross-talk between glomerular cells,
the signaling of Vascular Endothelial Growth Factor A
(VEGFA), Endothelin-1 (ET-1), and endothelial Nitric Oxide
Synthase (eNOS) between GEnCs and podocytes are described.
These molecules together form the VEGFA-eNOS/NO-ET-1 axis
between GEnCs and podocytes.
VEGFA-eNOS/NO-ET-1 Axis
VEGFA is synthesized by podocytes and binds to its receptors
VEGFR1 and VEGFR2 expressed on GEnCs (Eremina et al.,
2008). Under physiological conditions, VEGFA induces eNOS
activation in GEnCs and a subsequent increase in NO
production. The increase of NO may negatively regulates the
amount of VEGFA produced by podocytes (Mooyaart et al.,
2011). Via this crosstalk, the glomerular cells ensure that
sufficient VEGFA is produced to maintain viability of GEnCs,
without VEGFA levels rising to a level that induces sprouting
angiogenesis by GEnCs. In addition to NO, VEGFA also
regulates ET-1 production by GEnCs, since VEGFA blockage
in podocytes induces ET-1 release from GEnCs (Collino et al.,
2008). GEnCs are considered the principal source of ET-1 within
the glomeruli (Herman et al., 1998). ET-1 exerts its effect via
ET-1 receptors (ETR) A and ETRB. Low levels of ET-1 induce an
increase in NO, whereas high levels of ET-1 inhibit NO
production (Watschinger et al., 1995; Dong et al., 2005; Sud
and Black, 2009). ET-1 release from GEnCs associates with
cytoskeleton redistribution with a decrease of nephrin in
podocytes (Lenoir et al., 2014; Yuan et al., 2019). NO, in its
turn, inhibits ET-1 expression (Khimji and Rockey, 2010) and
exerts protective effects in podocytes (Sun et al., 2013). An
illustration of cross-talk between GEnCs and podocytes in the
VEGFA-eNOS/NO-ET-1 axis is provided in Figure 2. Next to
the effect of ET-1 on podocytes, ET-1 also exerts effects on
mesangial cells. ETRA signaling is associated with inflammation,
contraction and proliferation of mesangial cells (Barton and
Sorokin, 2015), and fibrosis. ETRB signaling has a reciprocal
effect and is associated with vasorelaxation via eNOS-derived
NO release (Barton and Yanagisawa, 2008).
GLOMERULAR SCLEROTIC DISEASES:
HISTOPATHOLOGY OF FSGS AND DN
DN is a long-term complication of both type 1 and type 2 diabetes
mellitus and develops in 20%–40% of all diabetes mellitus patients
(Rossing et al., 2018). DN, together with Focal Segmental
Glomerulosclerosis (FSGS), is the most important cause of
chronic kidney disease (CKD). Two types of FSGS exist:
primary (or idiopathic) FSGS and secondary FSGS. In primary
FSGS, which comprises 80% of all FSGS cases, the etiology is
unknown. Secondary FSGS is induced by a preexisting pathologic
condition, e.g., hypertension (Jefferson and Shankland, 2014), a
viral infection, such as human immunodeficiency virus, drug-
induced, or induced by genetic mutations (Lim et al., 2016). In
case of primary or mutation-induced FSGS, mutations in genes
encoding proteins expressed in podocytes, which are mostly
related to slit diaphragm structure, the actin cytoskeleton, or
foot processes, such as nephrin (NPHS1), podocin (NPHS2),
actinin a4 (ACTN4), and TRPC6 are commonly observed (Lim
et al., 2016). No mutations are known in GEnC-specific genes that
would cause FSGS.
FSGS and overt diabetic nephropathy (DN) both are
characterized by scarring (sclerosis) of the glomerular tuft, i.e.,
glomerulosclerosis (Figure 3). Glomerulosclerosis causes
obliteration of the glomerular capillaries eventually (Fioretto and
Mauer, 2007; De Vriese et al., 2018). In FSGS, only a fraction of the
glomeruli (i.e., focal) is affected in a segmental manner, i.e., part of
FIGURE 2 | Glomerular cross-talk between GEnC and podocytes via the
VEGFA-eNOS/NO-ET-1 axis. VEGFA, Vascular Endothelial Growth Factor A;
VEGFR1/2, VEGF Receptor 1 and 2; eNOS, endothelial Nitric Oxide
Synthase; NO, Nitric Oxide; ET-1, Endothelin-1; ETRA/B, ET-1 Receptor A
and B. Stimulating and inhibitory effects are indicated with arrows and blunt
lines, respectively.
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a glomerulus is affected. Sclerosis in FSGS is characterized by
deposition of extracellular matrix (ECM) at the capillary loops.
DN is the specific histopathology associated with reduced renal
function in patients suffering from diabetic kidney disease
(Yamanouchi et al., 2020). Overt DN comprises diffuse and
sometimes nodular glomerulosclerosis in many glomeruli,
caused by mesangial cell proliferation and mesangial sclerosis,
and develops primarily in patients with proteinuria. Of note,
nonproteinuric diabetic kidney disease also exists and which is
characterized byminor histopathological changes without DN and
with better prognosis compared with proteinuric diabetic kidney
disease (Yamanouchi et al., 2020). So, particularly FSGS but also
DN are accompanied by proteinuria (macroalbuminuria: >300
mg/gr creatinine), as well as by glomerular hypertension and
hyperfiltration, and activation of glomerular inflammatory
pathways (Fioretto and Mauer, 2007; Reidy and Kaskel, 2007).
At the ultrastructural level, damage to podocytes and GEnCs is
observed. Podocyte injury is observed as extensive effacement of
the foot processes, ultimately leading to detachment of podocytes
from the GBM (podocyte loss). GEnC dysfunction is characterized
morphologically as a reduction of the endothelial glycocalyx, loss
of fenestrae, widening of the subendothelial space, and swelling of
the cytoplasm (Weil et al., 2012; Eleftheriadis et al., 2013; Morita
et al., 2015; Taneda et al., 2015; Boels et al., 2016). In many
patients, DN and FSGS progresses into end-stage renal disease
(ESRD). Therapy resistance and the failure to adequately treat
proteinuria, a glomerular inflammatory phenotype and
hypertension are the main reasons for progression towards
ESRD (Kiffel et al., 2011; Collins et al., 2013). Renal replacement
therapy (dialysis or kidney transplantation), is the only effective
treatment to postpone premature death in ESRD patients (Collins
et al., 2014).
GENC DYSFUNCTION IN DN AND FSGS
GEnC dysfunction is important in the pathogenesis of
glomerular sclerotic diseases, including FSGS and overt DN.
GEnCs, covered by a thick glycocalyx, form the first cellular
barrier in direct contact with all circulating factors. Changes in
these circulating factors, such as high glucose levels and advanced
glycation end-products, can induce GEnC dysfunction (Singh
et al., 2011; Singh et al., 2013; Peng et al., 2016). In FSGS, the
development of mesangial matrix expansion and sclerosis by
parietal epithelial cells appears to be secondary to podocyte
injury, whereas in DN mesangial matrix expansion is the key
morphologic finding (Najafian et al., 2015). It is likely that GEnC
dysfunction precedes and possibly also contributes to podocyte
damage andmesangial expansion. In the past decade, evidence has
been provided that also GEnC dysfunction is present and plays an
important role in FSGS and DN development. GEnC dysfunction
occurs in the early stages of FSGS and DN, and is sufficient to
cause podocyte injury, proteinuria and activation of mesangial
cells, as will be discussed in detail below. An interdependent
relationship between GEnCs, podocytes and mesangial cells
exists, which involves bidirectional cross-talk with intercellular
signaling. Disturbed molecular cross-talk involving for example
endothelial nitric oxide synthase (eNOS) may result in reduced
GEnC-derived NO exposure to podocytes and can induce
podocyte damage, and eventually compromise glomerular
integrity (Yuen et al., 2012). Therapies aiming to prevent
endothelial injury have shown to reduce DN in animal models.
For example ETRA blockers have shown to restore the endothelial
glycocalyx and to reduce albuminuria in diabetic mice (Boels et al.,
2016). In diabetic patients, the ETRA blocker atrasentan reduced
urinary albumin to creatinine ratios (Lin et al., 2018).
Furthermore, renal elevation of cGMP, a key messenger for NO
signaling, resulted in a reduction of glomerulosclerosis in rats with
DN (Boustany-Kari et al., 2016). Given that GEnCs are the first
cells exposed to changes in circulating factors and that GEnC
behavior directly influences podocyte function, it is conceivable
that GEnC dysfunction may culminate in podocyte damage and
mesangial activation. It is, however, elusive which molecular
mechanisms underlie GEnC dysfunction and the subsequent
altered cross-talk with podocytes and mesangial cells. To
develop new treatment options in order to halt the progression
A B
FIGURE 3 | Glomerulosclerosis in DN (A) and FSGS (B). Light microscopy photomicrographs of a glomerulus showing DN with characteristic nodular mesangial
expansion (Kimmelstiel-Wilson lesions) (Periodic acid–Schiff staining) (A), and of a glomerulus with mild FSGS (methenamine-silver staining) (B). Nuclei are stained in blue.
Both glomeruli presenting glomerulosclerosis with increased glomerular extracellular matrix deposition and obliteration of capillaries. Scale bars represent 50 µm.
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of glomerular sclerotic disease, a deeper understanding of the
pathogenetic mechanisms underlying GEnC dysfunction and the
disturbed cross-talk is required. Hereunder, it is described that
GEnC dysfunction comprises multiple facets and is a pivotal and
early factor in the development of glomerulosclerosis and is at the
basis of developing proteinuria, podocyte dysfunction and
mesangial expansion in FSGS and DN.
Compromised Endothelial Glycocalyx in
DN and FSGS
Healthy GEnCs are covered with an endothelial glycocalyx. The
endothelial glycocalyx consists of glycoproteins, glycolipids and
proteoglycans with bound GAGs. Proteoglycans with bound
GAGs, of which heparan sulphate and hyaluronan constitute
up to 90%, are the main contributors to the function and
structure of the endothelial glycocalyx (Reitsma et al., 2007;
Slater et al., 2012; Garsen et al., 2014; Dane et al., 2015). In DN
and FSGS, the endothelial glycocalyx is reduced, characterized by
a loss of essential GAGs, including heparan sulphate and
hyaluronan, and reduced thickness (Nieuwdorp et al., 2006a;
Kuwabara et al., 2010; Satoh et al., 2010; van den Berg et al.,
2019). Environmental factors, such as elevated levels of glucose,
oxidative stress, or inflammatory stimuli, can modulate the
endothelial glycocalyx (Singh et al., 2011; Singh et al., 2013;
Kolarova et al., 2014). Inflammatory mediators like cytokines
and chemokines cause degradation of the endothelial glycocalyx.
Under physiological conditions, adhesion molecules on
endothelial are covered by the endothelial glycocalyx, and only
become accessible to leukocytes upon degradation of the
glycocalyx (Kolarova et al., 2014). In vivo, intravenous
administration of the bacterial heparan sulphate-degrading
enzyme heparinase enhances leukocyte adherence to
endothelial cells (Constantinescu et al., 2003). High glucose
and oxidative stress cause a reduction of heparan sulphate in
the endothelial glycocalyx on GEnCs in vitro (Singh et al., 2011;
Singh et al., 2013). Furthermore, high glucose reduces GAG
biosynthesis in GEnCs (Singh et al., 2011). Reduction of heparan
sulphate culminates in increased passage of albumin across a
GEnC monolayer (Singh et al., 2011; Singh et al., 2013). In line
with these in vitro data, a reduced endothelial glycocalyx
instantly causes proteinuria in vivo (Gil et al., 2012).
Preservation of the endothelial glycocalyx by the genetic
deletion of the heparan sulphate-degrading enzyme heparanase
prevents proteinuria and kidney failure in experimental DN and
glomerulonephritis (Gil et al., 2012; Garsen et al., 2016a). Loss of
endothelial hyaluronan and thereby the endothelial glycocalyx
induced by an endothelial-specific deletion of the hyaluronan
synthesis enzyme hyaluronan synthase 2 (HAS2) (van den Berg
et al., 2019) or by treatment with the hyaluronan-degrading
enzyme hyaluronidase (Meuwese et al., 2010) also induces
proteinuria (Meuwese et al., 2010; van den Berg et al., 2019)
and progressive glomerulopathy (van den Berg et al., 2019),
phenocopying the events in DN. In addition to the induction of
leukocyte adherence and proteinuria, degradation of the
endothelial glycocalyx also compromises GEnC signaling via
the loss of mechanosensing. Fluid shear stress induces the
production of NO in endothelial cells via activation of eNOS
(Boo et al., 2002). Fluid shear stress-induced NO production is
almost completely inhibited upon enzymatic removal of heparan
sulphate in the endothelial glycocalyx (Florian et al., 2003), due
to loss of eNOS activation. Impaired eNOS activation has
negative effects on both GEnCs and podocytes in vivo as this
results in GEnC dysfunction and disturbed cross-talk with
podocytes (Yuen et al., 2012). A reduced endothelial glycocalyx
on GEnCs, in response to noxious stimuli, clearly induces
glomerular inflammation, proteinuria, and disturbs GEnC
signaling. Loss of the endothelial glycocalyx coincides with
coagulation activation (Nieuwdorp et al., 2006b) and could
possibly also be linked with complement activation (Boels
et al., 2013), which is described elsewhere (Nieuwdorp et al.,
2006b; Boels et al., 2013) and will not further be addressed here.
Compromised Barrier Function by
Endothelial Cell-Selective Adhesion
Molecule (ESAM)
The barrier function of GEnCs in FSGS or DN is mainly
compromised by a reduction of the endothelial glycocalyx but
additional factors that contribute to an increased permeability
have been described as well. The altered expression of endothelial
cell-selective adhesion molecule (ESAM) has been implied in the
loss of the endothelial cell barrier in DN. ESAM is a surface
protein laterally expressed on GEnCs that is part of the
endothelial tight junctions, and mediates the interaction
between endothelial cells. ESAM expression is reduced in the
early course of DN (4 weeks) and is associated with increased
vascular permeability in vitro. In vivo, genetic ablation of ESAM
causes proteinuria, a decrease in GEnC fenestrations and an
increased space between GEnCs through expanded tight
junctions, while no structural changes are observed in
podocytes, the GBM and mesangium (Hara et al., 2009).
Therefore, these observations provide evidence that solely
GEnC dysfunction (induced by ESAM deficiency) already leads
to glomerular paracellular albumin leakage with preserved
podocyte structure (Hara et al., 2009).
Pro-Inflammatory Phenotype
GEnC dysfunction also contributes to glomerulosclerosis via
obtaining a pro-inflammatory phenotype without having direct
effects on podocytes and mesangial cells. Inflammatory pathways
are involved in the pathogenesis of DN and FSGS (Navarro-
Gonzalez et al., 2011; Wada and Makino, 2013; Moreno et al.,
2018; Wilkening et al., 2020). Inflammation-related molecules and
pathways (but without pronounced inflammation) may promote
fibrotic and proliferative responses of mesangial cells, culminating
in glomerulosclerosis (Furuta et al., 1993; Fogo, 2007). GEnC
activation plays an important role in glomerular leukocyte
infiltration as GEnC activation enables leukocyte rolling,
adhesion, arrest and transmigration across the endothelial cell
lining (Ley et al., 2007). Upon GEnC activation, the expression of
chemokines and adhesion molecules on the cell surface of GEnCs,
such as E-selectin (Hirata et al., 1998), intercellular adhesion
molecule 1 (ICAM-1) and monocyte chemoattractant protein 1
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(MCP-1), are increased (Rao et al., 2017). The high glucose-induced
toxic metabolites advanced glycation end-products (AGEs), induce
the expression of ICAM-1 and MCP-1 in a Rho-kinase dependent
manner. AGE-induced activation of Rho-kinase could be a result of
activation of the receptor for AGEs (RAGE) (Hirose et al., 2010).
Also ET-1 can activate Rho-kinase in endothelial cells (Gien et al.,
2013). Blockage of Rho-kinase in DNmice reduces the expression of
ICAM-1 and MCP-1, and ablates concomitant glomerular
infiltration of macrophages and glomerulosclerosis. Since
macrophages also display Rho-kinase, an endothelial-specific
inducible Rho-kinase gene targeting approach would be needed to
confirm the role of endothelial Rho-kinase in the increased
expression of ICAM-1 and MCP-1 in DN. This implies that
AGEs-induced expression of adhesion molecules on GEnCs plays
a key role in the development of diabetic glomerulosclerosis (Rao
et al., 2017). Indeed, inhibition of AGEs reduces glomerulosclerosis
in diabetic mice (Wilkinson-Berka et al., 2002; Forbes et al., 2003).
In addition to the increased expression of adhesion molecules,
GEnCs show a reduced expression of endothelial-specific
molecule-1 (ESM-1), already in very early stages of DN. Under
physiological conditions, GEnCs constitutively express ESM-1 that
functions as an anti-inflammatory molecule and inhibits migration
and rolling of leukocytes. Four weeks after the induction of diabetes,
before the development of histological glomerular changes
indicative of DN, ESM-1 expression was decreased in glomeruli
of DN-susceptible mice compared to glomeruli of DN-resistant
mice. These observations demonstrate that in early stages of DN,
GEnCs display a pro-inflammatory phenotype which precedes
glomerular damage (Zheng et al., 2017).
Mitochondrial Damage
In DN and FSGS, GEnCs display oxidative mitochondrial DNA
lesions and mitochondrial oxidative stress, which is associated
with loss of GEnC fenestrations (Daehn et al., 2014; Qi et al.,
2017) and a loss of the endothelial glycocalyx (Ebefors et al.,
2019). Mitochondrial oxidative stress in GEnCs was mediated by
release of ET-1 by podocytes and the subsequent paracrine
ETRA activation in GEnCs (Daehn et al., 2014; Ebefors et al.,
2019). ET-1 induced an increase in heparanase mRNA
expression in GEnCs in vitro, which could explain the loss of
the endothelial glycocalyx upon release of ET-1 by podocytes in
vivo (Ebefors et al., 2019). Mitochondrial oxidative stress was
only observed in GEnCs and not in podocytes in streptozotocin
(STZ)-induced DN (Qi et al., 2017). Interestingly, mitochondrial
damage in GEnCs preceded podocyte loss, proteinuria, and
glomerulosclerosis in adriamycin-induced FSGS and STZ-
induced DN (Daehn et al., 2014; Qi et al., 2017). Scavenging of
mitochondrial superoxide by systemic administration of the
mitochondria-targeted potent antioxidant mitoTEMPO
prevented GEnC mitochondrial oxidative stress (Daehn et al.,
2014; Qi et al., 2017), the loss of fenestrations (Qi et al., 2017) and
the loss of the endothelial glycocalyx (Ebefors et al., 2019).
Attenuation of GEnC mitochondrial stress results in
ameliorated podocyte loss, demonstrating that mitochondrial
damage in GEnCs and the resulting production of
mitochondrial superoxide are important triggers for podocyte
loss (Daehn et al., 2014; Nagasu et al., 2016; Qi et al., 2017).
eNOS Inactivation
eNOS inactivation, due to impaired dimerization and
phosphorylation, has been suggested to play an important role
in experimental DN (Cheng et al., 2012). In mice, resistant for
adriamycin-induced glomerulopathy, administration of
adriamycin induced massive proteinuria and severe
glomerulosclerosis upon eNOS deficiency. This observation
shows that loss of eNOS increases the susceptibility for the
development of adriamycin-induced nephropathy. GEnC
dysfunction, observed as loss of CD31 and apoptosis, appeared
3 days after adriamycin administration. Notably, podocyte
damage (i.e., loss of synaptopodin expression and apoptosis),
occurred only after 7 days, demonstrating that GEnC
dysfunction preceded podocyte damage in this model (Sun
et al., 2013). Part of these in vivo results could be explained by
adriamycin’s ability to induce inflammatory effects (Abou El
Hassan et al., 2003). In line with these findings it has been shown
that eNOS prevents heparanase expression and the development
of proteinuria in adriamycin-induced experimental FSGS
(Garsen et al., 2016b). In vitro, conditioned medium from
eNOS-overexpressing microvascular endothelial cells protected
podocytes from TNF-a-induced synaptopodin loss, suggesting
that “healthy” GEnCs protect podocytes from an inflammatory
insult in a paracrine manner by secreting protective mediators.
Which mediators are secreted by GEnCs and how these
mediators affect podocytes is not known (Sun et al., 2013).
Disturbed Crosstalk in the VEGFA-eNOS/
NO-ET-1
Disturbances in paracrine signaling of VEGFA, eNOS/NO, and
ET-1 between podocytes to GEnCs are critical and may
compromise glomerular integrity. Either increased or decreased
VEGFA expression, decreased eNOS signaling and increased ET-
1 signaling are all implicated in glomerular pathology. In mice,
gain of VEGFA in podocytes and lack of eNOS causes the
development of proteinuria and nodular glomerulosclerosis
(Veron et al., 2014). Podocyte-specific deletion of VEGFA
causes GEnC damage, observed as swelling of GEnCs, necrosis
and culminating in capillary obliteration (Eremina et al., 2008)
and loss of fenestrae (Eremina et al., 2003). Additionally,
podocyte-specific deletion of VEGFA also causes a loss of
GEnCs in diabetic mice (Sivaskandarajah et al., 2012). Whole-
body deletion of VEGFR2 results in a loss of viable GEnCs (Sison
et al., 2010). Also podocyte-specific VEGFA overexpression
results in loss of GEnCs and collapse of capillary loops
(Eremina et al., 2003) and causes advanced DN with
endothelial swelling (Veron et al., 2011), suggesting the
existence of a delicate balance between the protective and
deleterious effects of VEGFA, depending on the strength of
signaling. Deletion of eNOS causes GEnC dysfunction and
subsequently podocyte damage (Yuen et al. , 2012).
Administration of NO to cultured podocytes increases the
production of cyclic guanosine monophosphate (cGMP),
which controls the cytoskeletal structure of podocytes and
limits podocyte retraction (Sharma et al., 1992). Deletion of
eNOS and decreased availability of NO probably causes
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decreased cGMP production and subsequent podocyte retraction
and foot process effacement. Maintenance of endothelial eNOS
levels by the essential eNOS cofactor tetrahydrobiopterin
ameliorates DN (Kidokoro et al., 2013). Furthermore,
treatment with sepiapterin, a stable precursor of the eNOS
cofactor tetrahydrobiopterin or L-arginine, the nitric oxide
precursor induces a correction of eNOS dimerization and
phosphorylation and decreases albuminuria (Cheng et al.,
2012). In a recent paper, it was shown that ET-1 induces
heparanase expression in podocytes, which was associated with
a reduced glomerular endothelial glycocalyx in experimental
diabetes and which could be prevented in a podocyte-specific
ETR deficient mouse model nephropathy (Garsen et al., 2016c).
The mechanisms underlying the trafficking of podocyte-derived
VEGFA and heparanase against the filtration direction remain to
be identified, but may involve heparan sulfate present in
the GBM.
These studies demonstrate that the VEGFA-eNOS/NO-ET-1
signaling pathway is important for intraglomerular cross-talk
between podocytes and GEnCs, and the strength and direction of
signaling is critical for glomerular health. Disturbed cross-talk
causes glomerular damage. GEnCs are the first cells in contact
with all circulating factors in the blood. It is therefore likely that
GEnC dysfunction, culminating in altered secretion of signaling
molecules, occurs prior to, and is in fact (partly) responsible for
podocyte damage and activation of mesangial cells. GEnC
dysfunction might therefore be a leading initiating factor in the
development of both FSGS and DN.
Other Aberrant Molecular Signaling and
Expression Patterns
LRG1 and Enhancement of TGF-b/ALK1 Signaling
Recently, transcriptome profiling of GEnCs obtained from
diabetic mice showed increased gene expression of leucine-rich
a-2-glycoprotein (LRG1) in early stages of DN (Fu et al., 2018).
LRG1 is a protein present in the glomeruli and is predominantly
expressed by GEnCs. LRG1 is involved in angiogenesis and the
pathogenesis of DN by enhancement of endothelial Tumor
Growth Factor b (TGF-b)/activin receptor-like kinase 1
(ALK1) signaling. TGF-b signaling has previously been found
to be involved in the pathogenesis of DN by promoting cell
hypertrophy, ECM accumulation in the mesangium, and
increasing glomerular permeability (Chang et al., 2016). Global
genetic ablation of LRG1 led to a reduction of oxidative damage
and glomerular angiogenesis in diabetic mice. Concomitantly,
podocyte foot process effacement, podocyte loss, proteinuria, and
glomerulosclerosis were attenuated. These results exemplify that
alterations in GEnC gene expression and molecular pathways in
early disease mediate podocyte damage and glomerulopathy
(Hong et al., 2019). How increased LRG1 expression and TGF-
b signaling in GEnCs specifically relate to podocyte damage was
not addressed in these studies.
GEnC-Derived Exosomes
As a consequence of high glucose concentration, GEnCs show an
increased secretion of exosomes containing TGF-b1 mRNA. In
vitro, these exosomes induced mesangial cells to proliferate and
produce ECM (Wu et al., 2016) and caused the induction of
epithelial-mesenchymal-transition in podocytes (Wu et al.,
2017). Injection of exosomes, derived from high glucose-
treated GEnCs in vitro, caused glomerulosclerosis in mice (Wu
et al., 2016). These studies together suggest that high glucose-
induced GEnC dysfunction increases the production of GEnC
exosomes, which induce phenotypic changes in mesangial cells
and podocytes in vitro, and culminate in glomerulosclerosis in
vivo (Wu et al., 2016).
Hypoxia-Induced Dysregulation of GEnCs
DN is associated with renal cortical hypoxia (O’Neill et al., 2015).
Hypoxia and concomitant dysregulation of hypoxia-regulated
transcriptional mechanisms in GEnCs are associated with the
pathogenetic mechanisms involved in both FSGS and DN
development. Endothelial PAS domain-containing protein 1
(EPAS1) is an isoform of hypoxia inducible factor (HIF), also
known as HIF-2a. Endothelial-specific deletion of EPAS1
induced the loss of GEnC fenestrations and enhanced
endothelial swelling in experimental hypertension-induced
secondary FSGS. Additionally, GEnC dysfunction was
associated with podocyte foot process effacement and
worsening of proteinuria and glomerulosclerosis. In the
presence of hypertension and EPAS1, podocyte lesions were
not observed, demonstrating that aberrant EPAS1-mediated
endothelial signaling associates with podocyte damage and
exacerbates FSGS (Luque et al., 2017). Potential mechanisms
for aforementioned results include a direct effect of EPAS1 on
endothelial-dependent vasoreactivity and modulation of
glomerular pressure resulting in hyperfiltration, as mechanical
stress is thought to contribute to FSGS. Hyperfiltration results in
glomerular hypertrophy, culminating in loss of podocytes and
aggravation of mechanical stress and glomerular damage.
Furthermore, EPAS1 was previously shown to associate with
the assembly of intercellular adherens junctions and enhanced
endothelial barrier integrity (Gong et al., 2015). The involvement
of dysregulation of hypoxia-associated mechanisms in GEnCs in
the pathogenetic pathways leading to glomerular disease is
further substantiated by a study showing that endothelial-
specific knockout of hypoxia inducible factor 1a (HIF1a)
prevents the development of proteinuria and collagen
deposition in hypertensive FSGS (Luo et al., 2015). These and
the previous mentioned results show that HIF1a is detrimental,
whereas EPAS1/HIF2a confers protection in glomerular disease.
An explanation could be that the target genes of HIF1a and
HIF2a differ in a context-dependent manner (Dengler et al.,
2014). Collectively, the aforementioned studies show that
disturbed hypoxia-driven signaling in GEnCs contributes to
the pathogenesis of glomerular damage in FSGS and DN.
GEnC Plasticity: Endothelial-to-
Mesenchymal Transition
GEnC dysfunction can induce the process of endothelial-to-
mesenchymal transition (EndMT). Whether EndMT is an
initiating event in glomerulosclerosis, and to which extent
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EndMT contributes to glomerulosclerosis is not known. EndMT is
a process in which endothelial cells show an abrogated endothelial
phenotype (such as loss of the expression of endothelial cell
markers CD31 and VE-cadherin) and loss of endothelial
characteristics such as an increased vascular permeability. Loss
of endothelial marker expression coincides with an increase of
mesenchymal marker expression such as a-smooth muscle actin
(aSMA) and fibroblast specific protein 1 (FSP-1), and the
production of ECM proteins (Dejana et al., 2017). In general,
endothelial cells are suggested to contribute to the number of
activated fibroblasts via EndMT. EndMT most probably
contributes to fibrosis and is observed in cardiac and cancer-
related fibrosis (Zeisberg et al., 2007), fibro-proliferative vascular
disease (Moonen et al., 2015), but also in experimental kidney
disease as shown in streptozotocin (STZ)-induced DN, unilateral
ureteral obstruction, and a mouse model for Alport’s syndrome
(Zeisberg et al., 2008). In these models, ~30%–50% of the activated
fibroblasts co-express the endothelial cell marker CD31 and
mesenchymal markers, such as aSMA and FSP-1 (Zeisberg
et al., 2008). In lineage tracing experiments in STZ-induced
diabetic mice, interstitial endothelial cells acquired a more
mesenchymal-like phenotype by expressing aSMA, already early
in development of renal interstitial fibrosis (Li et al., 2009). Also in
glomeruli of DN patients, EndMT is observed as demonstrated by
co-expression of endothelial and mesenchymal markers (Peng
et al., 2016; Liu et al., 2018). High glucose conditions and advanced
oxidation protein products will stimulate GEnCs to undergo
EndMT (Liang et al., 2016; Peng et al., 2016; Shang et al., 2017).
Together, aforementioned observations provide evidence that
GEnCs can acquire a mesenchymal-like phenotype and may
contribute to glomerular fibrosis in DN. The process of EndMT
is shown to be controlled by autophagy in endothelial cells
(Patschan et al., 2016; Wang et al., 2017). In diabetic mice,
deletion of autophagy in endothelial cells induced by the
endothelial-specific genetic deletion of Autophagy-Related Gene
5 (ATG5) caused endothelial cell lesions, podocyte foot process
broadening and effacement, and an increase of microalbuminuria.
These results exemplify the tight intercellular cross-talk between
GEnC and podocytes, in which GEnC dysfunction (induced by
ATG5 deficiency) leads to podocyte injury (Lenoir et al., 2015).
EPIGENETIC MODIFICATIONS: A
POTENTIAL MECHANISM INVOLVED IN
GENC DYSFUNCTION
The above mentioned facets of GEnC dysfunction in FSGS and
DN associate with altered gene and protein expression. A
quiescent endothelial phenotype is harbored by tight regulation
of the endothelial transcriptome, i.e., the full array of mRNA
transcripts produced (Brooks et al., 2002; Passerini et al., 2004;
Gimbrone and Garcia-Cardena, 2013). Epigenetic mechanisms
are involved in this regulation of the transcriptome of cells
(Eccleston et al., 2013). Epigenetic modifications can cause
changes in gene expression, without changing the DNA
sequence (Gibney and Nolan, 2010) and are self-perpetuating,
dynamic, and reversible in response to the environment
(Beckerman et al., 2014). Many factors can influence epigenetic
profiles, including hyperglycemia, hypoxia, and inflammation
(Lu et al., 2017). Epigenetic modifications can either be
beneficial, or hamper GEnC function by changing the
transcriptome, resulting in GEnC dysfunction and potentially
disturbed cross-talk and pathogenesis of FSGS and DN.
Epigeneticmodifications includeDNAmethylation and histone
modifications. In general, DNAmethylation is associatedwith gene
repression by changing the biophysical characteristics of the DNA
to bind transcription factors. DNA methylation can also inhibit
gene expression viamethyl binding proteins, which in turn recruit
transcriptional co-repressors. DNA methylation at genes can
modulate transcriptional elongation and alternative splicing
(Gibney and Nolan, 2010; Lu et al., 2017).
In addition to DNA methylation, epigenetic mechanisms also
include modifications of histones. The best-characterized histone
modifications involve methylation, acetylation, and
phosphorylation. Histone modifications stably alter the
conformation of chromatin, and thereby either enhance or
inhibit gene transcriptional activity depending on the type of
modification and the position of the modified residue within the
histone (Kouzarides, 2007; Berger et al., 2009). DN is associated
with aberrant DNA methylation in proximal tubules and
peripheral blood cells (Maghbooli et al., 2014), and DNA
methylation is recently shown to be present in GEnCs (Fu
et al., 2018). Histone modifications have previously been
shown to be involved in the pathogenesis of DN and FSGS
(Sun et al., 2017; Majumder et al., 2018), but not much is known
about altered histone modification patterns in GEnCs in DN or
FSGS. Recently, transcriptome profiling of GEnCs obtained from
diabetic mice with early DN, showed that many of the genes with
decreased expression were involved in epigenetic regulation,
suggesting altered epigenetic regulation in GEnCs in early
stages of DN (Fu et al., 2018). Lysine-specific demethylase 6A
(KDM6a), also known as Ubiquitously Transcribed
Tetratricopeptide Repeat X Chromosome (UTX) was one of
the genes found to be downregulated. KDM6a is a histone
demethylase that specifically demethylates lysine 27 of histone
3. Methylation of lysine 27 of histone 3 (H3K27me3), mediated
by the methyltransferase Enhancer of Zeste Homolog 2 (EZH2),
is associated with gene repression (Tan et al., 2014). The role of
EZH2 and H3K27me3 in GEnCs in DN and FSGS is yet
unknown. In podocytes, H3K27me3 was previously shown to
be decreased in DN, which associated with the extent of
podocyte damage due to activation of Notch signaling and
loss of quiescence (Majumder et al., 2018). Previous studies
showed that EZH2 plays a role in endothelial homeostasis and
is a modulator of a number of endothelial cell functions, such
as endothelial-leukocytes interactions and angiogenesis (Dreger
et al., 2012; Maleszewska et al., 2016). This is indicative for a role
of altered epigenetic modifications in GEnCs resulting in aberrant
and pathologic gene expression contributing to the pathogenesis of
DN. Alteration of epigenetic modifications is shown to be
beneficial. For example, inhibition of the demethylases Jumonji
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C domain–containing demethylases (JMJD3) and UTX attenuated
podocyte injury in diabetic mice (Majumder et al., 2018). Also in
an unilateral ureteric obstruction mouse model, inhibition of
EZH2 and H3K27me3 attenuated renal fibrosis (Zhou et al.,
2016). Our current knowledge about the contribution of an
altered epigenetic landscape to GEnC dysfunction and disturbed
cross-talk in DN and FSGS is limited. Therefore, expanding our
knowledge on the potential causative role of epigenetic
modifications in GEnCs is highly needed. Herewith, specific
mediators involved in epigenetic pathways involved in GEnC
dysfunction and disturbed cross-talk can be considered potential
targets for future therapies in the pathogenesis of DN and FSGS.
SUMMARY AND FUTURE PERSPECTIVES
As outlined above, podocytes and mesangial cells have
previously received a lot of attention in research on the
pathogenesis of FSGS and DN. However, the studies
summarized in this review show that GEnC dysfunction
occurs in the early stages of FSGS and DN, and contributes to
podocyte damage and mesangial activation, eventually
culminating in glomerulosclerosis. Several of the studies
described here show that GEnC dysfunction precedes
podocyte damage, and is sufficient to develop proteinuria.
This provides a new insight on the role of GEnCs in the early
phase in development of FSGS and DN. GEnC dysfunction is
characterized by a compromised endothelial glycocalyx, an
inflammatory phenotype, mitochondrial damage and oxidative
stress, aberrant signaling and EndMT, resulting in proteinuria,
podocyte damage or loss, mesangial activation, and ultimately
glomerulosclerosis (Figure 4). The glomerular endothelium
poses a potential efficacious cellular target to pharmacologically
halt disease development and progression in DN and FSGS.
Aberrant gene expression patterns largely contribute to GEnC
dysfunction and altered epigenetic mechanisms seem involved in
this aberrant transcriptome. To expand our understanding of the
cross-talk between GEnCs and other glomerular cells in health and
disease, isolated systems could be useful, such as co-cultured cells
and organoids. Co-culture systems of differentiated GEnCs and
podocytes (Li et al., 2016) and organoids (Hale et al., 2018) with
subsequent endothelial genetic and epigenetic characterization
and manipulation could be instrumental for understanding the
pathways involved in GEnC-podocyte cross-talk. Until now, the
knowledge of the epigenetic mechanisms involved in GEnC
dysfunction in DN and FSGS is scarce and needs to be expanded.
Transcriptome profiling of GEnCs in DN and FSGS is of
utmost importance to identify aberrantly expressed genes and
associated regulatory pathways. Epigenomic databases, such as
encyclopedia of DNA elements (ENCODE), in which chromatin
modifications on both DNA and histone proteins are mapped in
various cell lines (Consortium, 2012), could reveal potential
epigenetic modifications responsible for aberrant expression
patterns. Cell-specific delivery is needed to therapeutically
intervene in the epigenetic mechanisms involved in GEnC
dysfunction to avoid off-target cell effects. The identification of
epigenetic mechanisms involved in GEnC dysfunction can
effectively be studied with CRISPR-Cas9 technology in vitro
(Adli, 2018). However, cell-specific delivery of CRISPR-Cas is
still a huge challenge (Adli, 2018). The delivery of nucleotides,
such as siRNAs therefore is an approach with great potential for
intervention in GEnCs. As epigenetic modifications are regulated
FIGURE 4 | Proposed mechanism on the role of GEnC in the development of glomerular sclerotic diseases. Harmful environmental conditions, such as
hyperglycemia and hypoxia cause GEnC dysfunction. GEnC dysfunction is characterized by a compromised endothelial glycocalyx, an inflammatory phenotype,
mitochondrial damage and oxidative stress, aberrant signaling and EndMT, resulting in proteinuria, podocyte damage or loss, mesangial activation, and ultimately
glomerulosclerosis.
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by epigenetic enzymes, intervening in the expression of
epigenetic enzymes can influence the amount of epigenetic
modifications. Endothelial cell-specific delivery of siRNA is
feasible and this strategy has previously been used to successfully
deliver siRNA to inflamed endothelial cells, including specifically
GEnCs, and to decrease the expression of the target gene of interest
(Kowalski et al., 2014; Choi et al., 2017).
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